MRI of Neurometabolic Impairment in ALS and TIA Using Hyperpolarized Pyruvate

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516954-24-00

Enrollment

Registered

2024-09-12

Start date

2020-05-01

Completion date

Unknown

Last updated

2025-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALS (Amyotrophic Lateral Sclerosis), TIA (Transient Ischemic Attack)

Brief summary

Cerebral metabolism as assesed with 13C label exchange from hyperpolarized pyruvate to bicarbonate, lactate and alanine

Detailed description

Disease characterization from clinical exsamination, interviews and patient records.

Interventions

DRUGHyperpolarized [1-13C]pyruvate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Cerebral metabolism as assesed with 13C label exchange from hyperpolarized pyruvate to bicarbonate, lactate and alanine	—

Secondary

Measure	Time frame
Disease characterization from clinical exsamination, interviews and patient records.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026